What to Know About GLP-1 Medications and Weight Management Programs
Learn how Eden connects patients to licensed providers to explore GLP-1 medications as part of medical weight management programs.
Considering GLP-1 treatment while breastfeeding? Learn what’s known about semaglutide safety, current research gaps, and how to speak with your provider.
GLP-1 receptor agonists like semaglutide (the active ingredient in Wegovy®, Ozempic®, and Rybelsus®) have proven benefits for weight management and type 2 diabetes. However, for individuals who are breastfeeding, the safety of semaglutide during lactation remains uncertain due to limited clinical data.
This guide outlines current research findings, potential risks to infants, and considerations for discussing semaglutide use with your healthcare provider.
Semaglutide is a GLP-1 receptor agonist that supports metabolic health by:
FDA-approved uses include:
Semaglutide may support weight-related goals and glucose control under medical supervision.
A 2024 study analyzed breast milk samples from eight lactating women who received subcutaneous semaglutide. Using high-resolution liquid chromatography-mass spectrometry, researchers found no detectable levels of semaglutide in any samples collected at 0, 12, and 24 hours post-administration. The estimated relative infant dose (RID) was calculated at 1.26%, significantly below the 10% threshold considered acceptable for breastfeeding medications.
Animal studies have shown that semaglutide can transfer into breast milk in species like rats. However, due to differences in physiology and milk composition, these findings may not directly translate to humans.
While current human data is reassuring, potential concerns include:
Semaglutide influences insulin activity. If transferred through milk, it could potentially impact infant blood glucose levels.
In adults, semaglutide may cause nausea, vomiting, or diarrhea. Similar symptoms could occur in infants exposed through breast milk, although this is unconfirmed.
Appetite suppression or side effects like vomiting or diarrhea may decrease maternal caloric intake or hydration, potentially influencing milk production.
Current guidance from product labels advises against using semaglutide while breastfeeding due to the lack of safety data.
Most prescribing information, including that for Rybelsus®, advises patients to avoid semaglutide while nursing.
If you are breastfeeding and considering GLP-1 treatment, your provider may:
For postpartum individuals who are not breastfeeding, GLP-1 therapy may offer supportive benefits for:
Eden’s licensed providers can help determine if treatment is appropriate once lactation ends or if other medications may be considered in the meantime.
Semaglutide is a prescription-only medication available through licensed pharmacies. For safety:
{{primary-cta}}
Currently, semaglutide is not recommended during breastfeeding due to limited human data. While recent studies suggest minimal transfer into breast milk, the risk to nursing infants remains unclear.
If you're considering semaglutide for weight or blood sugar management, discuss your breastfeeding status and health goals with a licensed provider. Delaying treatment or exploring safer alternatives during lactation may be advised.
Eden helps individuals navigate GLP-1 options after weaning and provides access to personalized, provider-guided treatment with FDA-approved medications.
Please note that this is not meant to be medical advice; please consult with a licensed healthcare provider to determine what is best for your health.
This content is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, stopping, or modifying any treatment, especially during pregnancy or while breastfeeding.
Eden connects patients with licensed providers for personalized GLP-1 care using FDA-approved medications. Eden does not offer treatment during pregnancy or lactation and does not provide compounded medications.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Recent studies indicate minimal transfer into breast milk, but due to limited data, semaglutide is not currently recommended during lactation.
Yes, indirectly. Side effects such as nausea or dehydration may reduce calorie intake or fluid levels, which could impact milk supply.
Neither form is currently recommended. Both share the same active ingredient and lack sufficient safety data for use during lactation.
Most guidelines recommend waiting until at least two months after discontinuing breastfeeding and after discussing with your provider.
No. Eden does not support semaglutide treatment during lactation. Patients must disclose breastfeeding status during their consultation.